Skip to main content

Table 2 HRQL impact of psoriasis at baseline: study population versus general US population

From: Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

  Adalimumab Mean (SD)1 Placebo Mean (SD)2 General US Population3 Mean (SD)
Physical Functioning 48.6 (10.3) 48.2(10.6) 49.4 (10.0)
Role-Physical 48.2 (11.1) 48.7 (10.8) 50.1 (9.9)
Bodily Pain 47.5 (10.9) 47.4 (10.6) 49.2 (10.2)
General Health 49.5 (9.5) 50.2 (9.5) 49.3 (10.7)
Vitality 49.9 (9.8) 50.3 (10.3) 50.4 (10.5)
Social Functioning 46.0 (11.8) 46.1 (11.7) 50.1 (10.1)
Role-Emotional 47.6 (12.0) 47.4 (12.0) 50.6 (9.5)
Mental Health 47.4 (10.8) 47.9 (11.0) 49.4 (10.7)
  1. 1N = 804–808.
  2. 2N = 396–397.
  3. 3SF-36 values for males and females aged 45 to 54 years from SF-36 manual (1998 population); N = 417.